prIME Masterclass in Colorectal Cancer

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

Meeting Overview

This one-day live meeting is specifically designed to discuss the treatment of patients with metastatic colorectal cancer (mCRC) and early CRC. You will have the opportunity to interact with leading national and international multidisciplinary experts and gain valuable insight into the most up-to-date management concepts and emerging treatment strategies for patients with CRC. In addition to didactic presentations, this program will increase interactivity with the faculty via quiz questions (“brain teasers”), clinical case discussion, and tumor board discussions.

Date and Location

Saturday, 19 May 2018
08.30 – 16.00

Room: Yamato West/South
Hilton Tokyo
160-0023, Shinjuku-Ku
Tokyo, Japan

Date/Time

Date/Time

Saturday, 19 May 2018
08.30 – 16.00

Location

Location

Tokyo, Japan

IME

IME

Saturday, 19 May

08.30 Welcome, introduction, and demographics
René Adam, MD, PhD, Takayuki Yoshino, MD, PhD, and prIME Oncology Medical Director
08.40 Brain teasers
08.50 Keynote presentation I—New era of CRC management: Impact of tumor sidedness and molecular subtypes of CRC
Scott Kopetz, MD, PhD, FACP
09.15 Q & A
09.25 Pan-Asian ESMO-adapted guidelines for managing mCRC: Impact on clinical practice
Takayuki Yoshino, MD, PhD
09.50 Q & A

Session I: Optimizing outcomes in patients with CRC oligometastatic disease
Moderated by Jianmin Xu, MD, PhD

09.55 Liver-only metastases: Importance of multidisciplinary treatment approach
René Adam, MD, PhD
10.25 Clinical cases and multidisciplinary tumor board discussion
Yoshinori Kagawa, MD, PhD, Lam Ka On, MBBS, FRCR, FHKCR, FHKAM, and Yunfeng Yao, MD, PhD
11.10 Coffee break

Session II: First-line therapy and continuum of care approach in mCRC
Moderated by Scott Kopetz, MD, PhD, FACP

11.35 Selecting front-line therapy for mCRC
Kun-Huei Yeh, MD, PhD
11.55 Continuum of care in mCRC
Takayuki Yoshino, MD, PhD
12.15 Clinical cases and multidisciplinary tumor board discussion
Krittiya Korphaisarn, MD, Yao-Yu Hsieh, MD, and Chia-Lun Chang, MD
13.00 Lunch
14.00 Keynote presentation II—Immunotherapy in mCRC: MSI-high and beyond
Kei Muro, MD
14.25 Q & A

Session III: Management of early stage CRC
Moderated by Kun-Huei Yeh, MD, PhD

14.30 Advances in surgery and adjuvant therapy for early stage CRC
Jianmin Xu, MD, PhD
14.55 Clinical cases and multidisciplinary tumor board discussion
Koji Ando, MD, PhD, and Feng Wang, MD
15.25 Brain teasers revisited and faculty commentary
15.40 CRC in the coming years: What can we expect?
Scott Kopetz, MD, PhD, FACP
15.55 prIME Points™
René Adam, MD, PhD, and Takayuki Yoshino, MD, PhD
16.00 Adjourn

    Chairs

  • René Adam, MD, PhDHepato Biliary Centre at Paul Brousse Hospital
    Villejuif, France
  • Takayuki Yoshino, MD, PhDNational Cancer Center Hospital East
    Chiba, Japan
  • Faculty

  • Scott Kopetz, MD, PhD, FACPUniversity of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Kei Muro, MDAichi Cancer Center Hospital
    Nagoya, Japan
  • Jianmin Xu, MD, PhDZhongshan Hospital, Fudan University
    Shanghai, China
  • Kun-Huei Yeh, MD, PhDNational Taiwan University Hospital
    National Taiwan University Cancer Center
    Taipei, Taiwan

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals from the Asian Pacific region who are involved in the management of CRC.

After successful completion of this educational activity, participants should be able to:

  • Explain state-of-the-art management of early and metastatic CRC, and evaluate current and emerging biomarkers to guide personalized therapy
  • Identify multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with liver-only metastases
  • Select optimal front-line treatment for mCRC and assess sequencing strategies beyond disease progression
  • Evaluate treatment options for metastatic BRAF-mutant mCRC
  • Describe emerging agents in mCRC, including immunotherapy-based combinations

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.